• Expedeon Posts 68 Percent Rise in 2018 Revenues

    Expedeon Posts 68 Percent Rise in 2018 Revenues

    2019/04/28

    Expedeon today posted a 68 percent increase in revenues for full-year 2018 as the company benefited from sales generated by recent acquisitions. For the 12-month period ended Dec. 31, Expedeons revenues climbed to 13.1 million ($14.6 million......More>>

  • PerkinElmer Reports Slight Revenue Gains for Q1

    PerkinElmer Reports Slight Revenue Gains for Q1

    2019/04/28

    PerkinElmer reported after the close of the market on Thursday that total revenues for the first quarter of 2019 inched up a fraction of 1 percent year over year while revenues from its Diagnostics division grew 5 percent. For the three mont......More>>

  • iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assay

    iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assay

    2019/04/28

    iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China. The joint venture called Wondfo-iCubate Biotech will develop assays using iCubates amplicon-rescued......More>>

  • Abbott Q1 Diagnostics Revenues Flat

    Abbott Q1 Diagnostics Revenues Flat

    2019/04/28

    Abbott said Wednesday that its first quarter Diagnostics business revenues grew about 2 percent year over year, driven by long-term double-digit growth in its Alinity molecular diagnostic platform and other products. For the three months end......More>>

  • Improvement in CAR T-Cell Therapy Removes Severe Side Effect

    Improvement in CAR T-Cell Therapy Removes Severe Side Effect

    2019/04/28

    University of Southern California (USC) scientists havemade an advancement in chimeric antigen receptor (CAR) T-cell therapy that seems to eliminate its severe side effects, making the treatment safer and potentially available in outpatient......More>>

  • WuXi Biologics Completes First Routine FDA Inspection, Annou

    WuXi Biologics Completes First Routine FDA Inspection, Annou

    2019/04/28

    On April 17, 2019, WuXi Biologics, a provider of end-to-end solutions for biologics discovery, development, and manufacturing, announced that its drug substance (DS) and drug product (DP) manufacturing facilities at WuXi city successfully co......More>>

Copyright © 2018 CACLP